JCR Pharmaceuticals

4552 · TSE · Japan

Public Market Listing

4552TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for JCR Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
2Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Approved
HDACSmall molecule
Duchenne Muscular DystrophyPolycythemia Vera
remestemcel-L(Ryoncil)
Approved
Allogeneic MSC therapyCell therapy
Inflammatory Bowel DiseaseGraft-versus-Host Disease
Ulcerative Colitis, Crohn's Disease
JR-131No recent activity
Phase 3
Erythropoietin receptor (EPO-R)Biologic (subtype unspecified)
Chronic Kidney Disease

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
GivinostatPhase 2Chronic Myeloproliferative Neoplasms
Est. primary completion 2026-12 · NCT01761968 · CT.gov ↗
What to watch
2028 (2)
February 2028 (2)
GivinostatPhase 3Duchenne Muscular Dystrophy
Est. primary completion 2028-02 · NCT05933057 · CT.gov ↗
What to watch
remestemcel-L · RyoncilPhase 3GVHD - Graft-Versus-Host Disease
Est. primary completion 2028-02-28 · NCT07568535 · CT.gov ↗
What to watch
2029 (2)
December 2029 (2)
GivinostatPhase 2Duchenne Muscular Dystrophy
Est. primary completion 2029-12 · NCT06769633 · CT.gov ↗
What to watch
GivinostatPhase 2/3Duchenne Muscular Dystrophy
Est. primary completion 2029-12 · NCT03373968 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.